



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Oleclumab

Cat. No.:	HY-P99039
CAS No.:	1803176-05-7
Target:	CD73
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Oleclumab (MEDI9447) is a human IgG1 λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity ^{[1][2]} .								
In Vivo	<p>Oleclumab (10 mg/kg; ip; every 3 days for 4 doses) increases the proportion of activated CD8⁺ lymphocyte populations in the mouse Balb/c syngeneic CT26 colon cancer tumor model. And Oleclumab significantly inhibits tumor growth^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model^[2]</td></tr><tr><td>Dosage:</td><td>10 mg/kg</td></tr><tr><td>Administration:</td><td>ip; 2 time per week, for 2 weeks</td></tr><tr><td>Result:</td><td>Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.</td></tr></table>	Animal Model:	Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model ^[2]	Dosage:	10 mg/kg	Administration:	ip; 2 time per week, for 2 weeks	Result:	Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.
Animal Model:	Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model ^[2]								
Dosage:	10 mg/kg								
Administration:	ip; 2 time per week, for 2 weeks								
Result:	Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.								

REFERENCES

[1]. Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227.

[2]. Hay CM, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016 Jul 11;5(8):e1208875.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA